Szymon Zysiak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Szymon Zysiak has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Kurek
Military Institute of Medicine in Warsaw, Mazovia, Poland
9 shared publications - Aleksandra Lejman
10th Military Clinical Hospital with Independent Public Healthcare Centre Polyclinic in Bydgoszcz, Bydgoszcz, Poland
9 shared publications - Aleksandra Mazurkiewicz
1st Military Clinical Hospital with Outpatient Clinic in Lublin, Lublin, Poland
9 shared publications - Hubert Sidor
Military Institute of Medicine in Warsaw, Mazovia, Poland
9 shared publications - JęDrzej Zaguła
Military Institute of Aviation Medicine, Warsaw, Poland
9 shared publications - Monika Wołosik
Military Institute of Medicine in Warsaw, Mazovia, Poland
9 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
MODERN GLAUCOMA THERAPY: A NARRATIVE REVIEW
Introduction: Glaucoma is a chronic, progressive optic neuropathy and a major cause of irreversible vision loss worldwide. Because early disease is often asymptomatic, many patients are diagnosed after relevant structural damage has already developed. Lowering intraocular pressure (IOP) remains the primary therapeutic objective and the most established approach to reduce the risk of progression. This review summarizes current advances in glaucoma care, including modern pharmacological strategies, sustained-release therapy, neuroprotection research, microinvasive glaucoma surgery (MIGS), and diagnostic innovations. Methodology: A narrative review of PubMed, Scopus, and Google Scholar was performed to summarize recent evidence on modern glaucoma therapy and monitoring. Results: Recent progress in medical therapy includes agents targeting the conventional outflow pathway, updated prostaglandin-based approaches, and fixed-dose combinations that reduce regimen complexity. Long-acting drug delivery systems may decrease the reliance on daily eye drops, although safety and durability remain important considerations. Neuroprotection continues to attract strong research interest, but clinical evidence is still insufficient to support a widely accepted strategy beyond IOP lowering. MIGS provides intermediate surgical options that may reduce IOP and medication burden in selected patients, yet outcomes vary across techniques and study designs. OCT and OCT angiography support objective monitoring of structural and vascular changes and may improve detection of progression over time. Conclusion: Glaucoma care is becoming increasingly individualized through expanding therapeutic and monitoring strategies. Future research should focus on long-term standardized outcomes, improved progression biomarkers, and validation of disease-modifying approaches, including gene- and regenerative therapies.
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessMODERN GLAUCOMA THERAPY: A NARRATIVE REVIEW
Introduction: Glaucoma is a chronic, progressive optic neuropathy and a major cause of irreversible vision loss worldwide. Because early disease is often asymptomatic, many patients are diagnosed after relevant structural damage has already developed. Lowering intraocular pressure (IOP) remains the primary therapeutic objective and the most established approach to reduce the risk of progression. This review summarizes current advances in glaucoma care, including modern pharmacological strategies, sustained-release therapy, neuroprotection research, microinvasive glaucoma surgery (MIGS), and diagnostic innovations. Methodology: A narrative review of PubMed, Scopus, and Google Scholar was performed to summarize recent evidence on modern glaucoma therapy and monitoring. Results: Recent progress in medical therapy includes agents targeting the conventional outflow pathway, updated prostaglandin-based approaches, and fixed-dose combinations that reduce regimen complexity. Long-acting drug delivery systems may decrease the reliance on daily eye drops, although safety and durability remain important considerations. Neuroprotection continues to attract strong research interest, but clinical evidence is still insufficient to support a widely accepted strategy beyond IOP lowering. MIGS provides intermediate surgical options that may reduce IOP and medication burden in selected patients, yet outcomes vary across techniques and study designs. OCT and OCT angiography support objective monitoring of structural and vascular changes and may improve detection of progression over time. Conclusion: Glaucoma care is becoming increasingly individualized through expanding therapeutic and monitoring strategies. Future research should focus on long-term standardized outcomes, improved progression biomarkers, and validation of disease-modifying approaches, including gene- and regenerative therapies.
- 28 February 2026
- Published by European Scientific Society in Archiv Euromedica
- Vol. 16 (1)
GLP-1 receptor agonists and depression in obesity: current evidence
Background Obesity is closely associated with depression and emotional distress. Glucagon like peptide 1 receptor agonists have become widely used for obesity treatment, raising concerns about their potential psychiatric effects. While randomized controlled trials generally report neutral or mildly favorable mood outcomes, real world studies and pharmacovigilance data suggest heterogeneous signals, creating uncertainty regarding psychiatric safety. Aims To critically assess the association between GLP 1 receptor agonist therapy and depressive symptoms in adults with obesity by comparing evidence from randomized trials, real world observational studies, pharmacovigilance databases, and qualitative research published between 2022 and 2025. Methods A narrative review was conducted using PubMed. Original studies involving adults with overweight or obesity treated with GLP 1 receptor agonists and reporting psychiatric outcomes were included. Randomized trials, observational cohorts, pharmacovigilance analyses, and qualitative studies were synthesized narratively due to methodological heterogeneity. Results Randomized controlled trials consistently showed no increased risk of depression or suicidal ideation and, in some cases, modest mood improvement in selected populations without major psychiatric comorbidity. In contrast, real world and pharmacovigilance data revealed heterogeneous findings, including signals of depressive symptoms and anxiety in subsets of patients, limited by confounding and reporting bias. Qualitative evidence demonstrated substantial interindividual variability in emotional responses to treatment. Conclusions Current evidence does not support a causal association between GLP 1 receptor agonist therapy and clinically significant depression in adults with obesity. Discrepancies between data sources are largely attributable to methodological differences and population selection. Individualized assessment and clinical vigilance remain warranted, particularly in patients with underlying psychological vulnerability.
- 28 February 2026
- Published by European Scientific Society in Archiv Euromedica
- Vol. 16 (1)
GLP-1 receptor agonists and depression in obesity: current evidence
Background Obesity is closely associated with depression and emotional distress. Glucagon like peptide 1 receptor agonists have become widely used for obesity treatment, raising concerns about their potential psychiatric effects. While randomized controlled trials generally report neutral or mildly favorable mood outcomes, real world studies and pharmacovigilance data suggest heterogeneous signals, creating uncertainty regarding psychiatric safety. Aims To critically assess the association between GLP 1 receptor agonist therapy and depressive symptoms in adults with obesity by comparing evidence from randomized trials, real world observational studies, pharmacovigilance databases, and qualitative research published between 2022 and 2025. Methods A narrative review was conducted using PubMed. Original studies involving adults with overweight or obesity treated with GLP 1 receptor agonists and reporting psychiatric outcomes were included. Randomized trials, observational cohorts, pharmacovigilance analyses, and qualitative studies were synthesized narratively due to methodological heterogeneity. Results Randomized controlled trials consistently showed no increased risk of depression or suicidal ideation and, in some cases, modest mood improvement in selected populations without major psychiatric comorbidity. In contrast, real world and pharmacovigilance data revealed heterogeneous findings, including signals of depressive symptoms and anxiety in subsets of patients, limited by confounding and reporting bias. Qualitative evidence demonstrated substantial interindividual variability in emotional responses to treatment. Conclusions Current evidence does not support a causal association between GLP 1 receptor agonist therapy and clinically significant depression in adults with obesity. Discrepancies between data sources are largely attributable to methodological differences and population selection. Individualized assessment and clinical vigilance remain warranted, particularly in patients with underlying psychological vulnerability.
- 28 February 2026
- Published by European Scientific Society in Archiv Euromedica
- Vol. 16 (1)
WHEN ANXIETY IS ENDOCRINE-DRIVEN: HYPERTHYROIDISM AND THE SPECTRUM OF ANXIETY DISORDERS - NARRATIVE REVIEW
Background Hyperthyroidism and anxiety disorders are highly prevalent conditions that frequently coexist and present with substantial clinical overlap. Their comorbidity is associated with impaired functioning, reduced quality of life, and diagnostic challenges that may lead to delayed or incomplete treatment. Aims The aim of this narrative review was to systematize current evidence on the relationship between hyperthyroidism and anxiety disorders, with particular emphasis on shared pathophysiological mechanisms, clinical symptom overlap, impact on quality of life, and implications for interdisciplinary management. Methods A narrative review of the literature was conducted using publications identified in PubMed, PubMed Central, and Google Scholar. The search was performed between October 15 and November 10, 2025, without a strict time restriction. A total of 44 relevant sources, including narrative and systematic reviews, meta analyses, observational clinical studies, and experimental preclinical studies, were included and synthesized descriptively. Results The analyzed literature demonstrates a complex and bidirectional relationship between hyperthyroidism and anxiety disorders. Key findings indicate significant neuroendocrine dysregulation involving interactions between the hypothalamic pituitary thyroid and hypothalamic pituitary adrenal axes, alterations in neurotransmitter systems, autoimmune mediated processes, and emerging contributions of the gut brain axis. Clinically, substantial symptom overlap frequently complicates differential diagnosis, and anxiety symptoms often persist despite restoration of euthyroidism, leading to sustained impairment in quality of life. Conclusions Hyperthyroidism represents a clinically relevant and often underrecognized contributor to anxiety related symptomatology. Normalization of thyroid hormone levels alone is frequently insufficient to resolve psychiatric symptoms, underscoring the need for integrated interdisciplinary management. Future research should focus on longitudinal and interventional studies to clarify underlying mechanisms and to evaluate targeted psychiatric and endocrine treatment strategies aimed at improving long term functional outcomes and quality of life.
- 28 February 2026
- Published by European Scientific Society in Archiv Euromedica
- Vol. 16 (1)
WHEN ANXIETY IS ENDOCRINE-DRIVEN: HYPERTHYROIDISM AND THE SPECTRUM OF ANXIETY DISORDERS - NARRATIVE REVIEW
Background Hyperthyroidism and anxiety disorders are highly prevalent conditions that frequently coexist and present with substantial clinical overlap. Their comorbidity is associated with impaired functioning, reduced quality of life, and diagnostic challenges that may lead to delayed or incomplete treatment. Aims The aim of this narrative review was to systematize current evidence on the relationship between hyperthyroidism and anxiety disorders, with particular emphasis on shared pathophysiological mechanisms, clinical symptom overlap, impact on quality of life, and implications for interdisciplinary management. Methods A narrative review of the literature was conducted using publications identified in PubMed, PubMed Central, and Google Scholar. The search was performed between October 15 and November 10, 2025, without a strict time restriction. A total of 44 relevant sources, including narrative and systematic reviews, meta analyses, observational clinical studies, and experimental preclinical studies, were included and synthesized descriptively. Results The analyzed literature demonstrates a complex and bidirectional relationship between hyperthyroidism and anxiety disorders. Key findings indicate significant neuroendocrine dysregulation involving interactions between the hypothalamic pituitary thyroid and hypothalamic pituitary adrenal axes, alterations in neurotransmitter systems, autoimmune mediated processes, and emerging contributions of the gut brain axis. Clinically, substantial symptom overlap frequently complicates differential diagnosis, and anxiety symptoms often persist despite restoration of euthyroidism, leading to sustained impairment in quality of life. Conclusions Hyperthyroidism represents a clinically relevant and often underrecognized contributor to anxiety related symptomatology. Normalization of thyroid hormone levels alone is frequently insufficient to resolve psychiatric symptoms, underscoring the need for integrated interdisciplinary management. Future research should focus on longitudinal and interventional studies to clarify underlying mechanisms and to evaluate targeted psychiatric and endocrine treatment strategies aimed at improving long term functional outcomes and quality of life.
- Open Access
- 23 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
MODERN TECHNOLOGICAL SOLUTIONS IN THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA: A REVIEW OF INNOVATIONS AND THEIR SOCIAL IMPACT
Introduction: The aim of this review is to analyze technological advancements in the treatment of Obstructive Sleep Apnea (OSA) published between 2019 and 2025, with a specific focus on their impact on therapeutic adherence and public health. Materials and methods: A comprehensive literature review was conducted utilizing key databases such as PubMed, Scopus, Web of Science, and Google Scholar. The selection process prioritized innovative technological solutions, telemedicine applications, and e-health concepts. Results: The comprehensive review of the scientific literature revealed several technological advancements significantly impacting the treatment of Obstructive Sleep Apnea: Hypoglossal Nerve Stimulation: HNS serves as an effective alternative for moderate to severe OSA patients intolerant to CPAP [1]. This implantable treatment stimulates the hypoglossal nerve, activating muscles to maintain upper airway patency during sleep, resulting in significant reductions in Apnea-Hypopnea Index and improved sleep quality [2,3]. Advanced Algorithms in PAP Devices: Integrating AI and machine learning into PAP devices optimizes treatment and boosts patient adherence [4]. These algorithms analyze CPAP data to predict adherence issues, enabling clinicians to tailor interventions and personalize strategies for better patient outcomes [5]. Telemedicine: Telemedicine has advanced OSA management through remote patient interaction, monitoring, and follow-up [6]. This remote care often leads to comparable or improved treatment compliance, offering cost-effective solutions and increasing access to specialized care [7]. 3D Printing in Oral Appliances: 3D printing revolutionizes the fabrication of custom Mandibular Advancement Devices for OSA [8,9]. Utilizing digital workflows from intraoral scanning to CAD design, highly precise appliances are produced, improving patient comfort and adherence [9]. Conclusion: The introduction of new technologies in OSA treatment, such as hypoglossal nerve stimulation, improved algorithms in PAP devices, telemedicine, and 3D printing, holds significant potential for increasing patient therapeutic adherence [10]. These technologies favor therapy personalization, which is crucial given the diverse pathophysiology and phenotypes of OSA [2]. Improved compliance and the availability of personalized treatment methods directly translate into better public health outcomes, a reduction in the risk of cardiovascular and metabolic complications, and an overall improvement in the quality of life for OSA patients [11, 12]. However, attention must be paid to ensuring that the implementation of these innovations is conducted thoughtfully, so as not to exacerbate existing inequalities in access to healthcare [12].
- 23 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessMODERN TECHNOLOGICAL SOLUTIONS IN THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA: A REVIEW OF INNOVATIONS AND THEIR SOCIAL IMPACT
Introduction: The aim of this review is to analyze technological advancements in the treatment of Obstructive Sleep Apnea (OSA) published between 2019 and 2025, with a specific focus on their impact on therapeutic adherence and public health. Materials and methods: A comprehensive literature review was conducted utilizing key databases such as PubMed, Scopus, Web of Science, and Google Scholar. The selection process prioritized innovative technological solutions, telemedicine applications, and e-health concepts. Results: The comprehensive review of the scientific literature revealed several technological advancements significantly impacting the treatment of Obstructive Sleep Apnea: Hypoglossal Nerve Stimulation: HNS serves as an effective alternative for moderate to severe OSA patients intolerant to CPAP [1]. This implantable treatment stimulates the hypoglossal nerve, activating muscles to maintain upper airway patency during sleep, resulting in significant reductions in Apnea-Hypopnea Index and improved sleep quality [2,3]. Advanced Algorithms in PAP Devices: Integrating AI and machine learning into PAP devices optimizes treatment and boosts patient adherence [4]. These algorithms analyze CPAP data to predict adherence issues, enabling clinicians to tailor interventions and personalize strategies for better patient outcomes [5]. Telemedicine: Telemedicine has advanced OSA management through remote patient interaction, monitoring, and follow-up [6]. This remote care often leads to comparable or improved treatment compliance, offering cost-effective solutions and increasing access to specialized care [7]. 3D Printing in Oral Appliances: 3D printing revolutionizes the fabrication of custom Mandibular Advancement Devices for OSA [8,9]. Utilizing digital workflows from intraoral scanning to CAD design, highly precise appliances are produced, improving patient comfort and adherence [9]. Conclusion: The introduction of new technologies in OSA treatment, such as hypoglossal nerve stimulation, improved algorithms in PAP devices, telemedicine, and 3D printing, holds significant potential for increasing patient therapeutic adherence [10]. These technologies favor therapy personalization, which is crucial given the diverse pathophysiology and phenotypes of OSA [2]. Improved compliance and the availability of personalized treatment methods directly translate into better public health outcomes, a reduction in the risk of cardiovascular and metabolic complications, and an overall improvement in the quality of life for OSA patients [11, 12]. However, attention must be paid to ensuring that the implementation of these innovations is conducted thoughtfully, so as not to exacerbate existing inequalities in access to healthcare [12].
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
DIAGNOSTIC AND TREATMENT METHODS FOR URINARY TRACT INFECTIONS IN HEMATOLOGICAL PATIENTS
Research Objectives: To evaluate diagnostic and therapeutic methods for urinary tract infections (UTIs) in hematological patients, focusing on both conventional antimicrobial therapy and alternative treatment strategies in this immunocompromised population. Methods: Comprehensive literature review of diagnostic approaches including urine culture techniques, pathogen identification, and antimicrobial resistance patterns. Analysis of therapeutic strategies encompassing empirical and targeted antimicrobial therapy, alongside alternative modalities including cranberry supplementation, probiotics, urinary alkalinization, NSAIDs, and immunotherapy. Results: Hematological patients face elevated UTI risk (34.39% prevalence) with predominant pathogens including E. coli (19.99%) and Klebsiella spp. (5.12%), frequently exhibiting multidrug resistance. Rapid microbiological diagnosis with susceptibility testing is critical for preventing progression to urosepsis. Alternative therapies demonstrate prophylactic potential but cannot replace antimicrobial treatment in established infections. Conclusions: Effective UTI management in hematological patients requires rapid diagnostics, aggressive empirical therapy guided by local resistance patterns, and prompt de-escalation following susceptibility results. Alternative approaches serve valuable adjunctive roles but must not delay definitive antimicrobial therapy. Multidisciplinary collaboration and continuous protocol adaptation based on evolving resistance patterns optimize outcomes in this vulnerable population.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessDIAGNOSTIC AND TREATMENT METHODS FOR URINARY TRACT INFECTIONS IN HEMATOLOGICAL PATIENTS
Research Objectives: To evaluate diagnostic and therapeutic methods for urinary tract infections (UTIs) in hematological patients, focusing on both conventional antimicrobial therapy and alternative treatment strategies in this immunocompromised population. Methods: Comprehensive literature review of diagnostic approaches including urine culture techniques, pathogen identification, and antimicrobial resistance patterns. Analysis of therapeutic strategies encompassing empirical and targeted antimicrobial therapy, alongside alternative modalities including cranberry supplementation, probiotics, urinary alkalinization, NSAIDs, and immunotherapy. Results: Hematological patients face elevated UTI risk (34.39% prevalence) with predominant pathogens including E. coli (19.99%) and Klebsiella spp. (5.12%), frequently exhibiting multidrug resistance. Rapid microbiological diagnosis with susceptibility testing is critical for preventing progression to urosepsis. Alternative therapies demonstrate prophylactic potential but cannot replace antimicrobial treatment in established infections. Conclusions: Effective UTI management in hematological patients requires rapid diagnostics, aggressive empirical therapy guided by local resistance patterns, and prompt de-escalation following susceptibility results. Alternative approaches serve valuable adjunctive roles but must not delay definitive antimicrobial therapy. Multidisciplinary collaboration and continuous protocol adaptation based on evolving resistance patterns optimize outcomes in this vulnerable population.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
COBENFY (XANOMELINE-TROSPIUM CHLORIDE) AS A BREAKTHROUGH IN SCHIZOPHRENIA TREATMENT: POTENTIAL IMPACT ON PATIENT QUALITY OF LIFE AND HEALTHCARE ECONOMICS
In September 2024 FDA approved Cobenfy - the first antipsychotic with a novel mechanism of action in over 30 years. Unlike conventional antipsychotics that block D2 dopamine receptors, Cobenfy acts through muscarinic M1 and M4 receptor agonism. This matters because the side effects of traditional antipsychotics - weight gain, metabolic disturbances, movement disorders - are the main reason why about half of patients stop taking their medications. And when they stop, relapses follow. The EMERGENT trials demonstrated that Cobenfy achieves comparable efficacy (effect size 0.61) while avoiding the metabolic and extrapyramidal problems that plague existing treatments. For patients with schizophrenia, who already face a 15-20 year reduction in life expectancy largely due to cardiovascular disease, a medication that doesn't worsen their metabolic profile could be genuinely life-changing. But beyond individual health the implications extend to families exhausted by relapse cycles, to healthcare systems burdened by preventable hospitalizations, and to communities that have struggled to integrate people whose treatment makes normal functioning nearly impossible. Of course long-term data are still needed - approval came after relatively short trials. But the potential here is significant: better tolerability could mean better adherence, fewer relapses, less hospitalization, and ultimately patients who can actually participate in their own lives.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessCOBENFY (XANOMELINE-TROSPIUM CHLORIDE) AS A BREAKTHROUGH IN SCHIZOPHRENIA TREATMENT: POTENTIAL IMPACT ON PATIENT QUALITY OF LIFE AND HEALTHCARE ECONOMICS
In September 2024 FDA approved Cobenfy - the first antipsychotic with a novel mechanism of action in over 30 years. Unlike conventional antipsychotics that block D2 dopamine receptors, Cobenfy acts through muscarinic M1 and M4 receptor agonism. This matters because the side effects of traditional antipsychotics - weight gain, metabolic disturbances, movement disorders - are the main reason why about half of patients stop taking their medications. And when they stop, relapses follow. The EMERGENT trials demonstrated that Cobenfy achieves comparable efficacy (effect size 0.61) while avoiding the metabolic and extrapyramidal problems that plague existing treatments. For patients with schizophrenia, who already face a 15-20 year reduction in life expectancy largely due to cardiovascular disease, a medication that doesn't worsen their metabolic profile could be genuinely life-changing. But beyond individual health the implications extend to families exhausted by relapse cycles, to healthcare systems burdened by preventable hospitalizations, and to communities that have struggled to integrate people whose treatment makes normal functioning nearly impossible. Of course long-term data are still needed - approval came after relatively short trials. But the potential here is significant: better tolerability could mean better adherence, fewer relapses, less hospitalization, and ultimately patients who can actually participate in their own lives.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
ANTIDEPRESSANT-ASSOCIATED SEXUAL DYSFUNCTION (AASD) – FROM PATHOPHYSIOLOGY TO CLINICAL MANAGEMENT: A LITERATURE REVIEW
Major Depressive Disorder (MDD) presents a global challenge, with pharmacotherapy based on SSRIs and SNRIs remaining the standard of care. Despite clinical efficacy, the tolerability of these agents is often limited by iatrogenic Antidepressant-Associated Sexual Dysfunction (AASD), a leading cause of therapeutic non-adherence and so-called "hidden non-compliance," resulting in disease relapse. This paper provides a comprehensive literature review aimed at updating knowledge on epidemiology, neurobiological mechanisms extending beyond the serotonin hypothesis, and modern management strategies for AASD, with particular emphasis on Post-SSRI Sexual Dysfunction (PSSD). Databases including PubMed, ScienceDirect, Cochrane Library, and Google Scholar were searched, focusing on studies utilizing validated psychometric tools (e.g., ASEX, PRSexDQ). The analysis reveals a significant disparity between spontaneously reported AASD rates (10–15%) and those detected via screening (70–80%). A risk hierarchy was confirmed: paroxetine and venlafaxine demonstrate the highest iatrogenic potential, attributed partly to nitric oxide synthase inhibition and dopaminergic suppression. Vortioxetine and bupropion are characterized by a neutral profile, offering a safe alternative. The review also confirms the growing clinical importance of PSSD as a persistent complication. AASD requires proactive monitoring in daily practice. Results support moving away from a "wait and see" strategy in favor of routine screening and early implementation of switching or augmentation strategies. Personalization of pharmacotherapy is crucial for maintaining patient adherence and ensuring long-term depression treatment efficacy.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessANTIDEPRESSANT-ASSOCIATED SEXUAL DYSFUNCTION (AASD) – FROM PATHOPHYSIOLOGY TO CLINICAL MANAGEMENT: A LITERATURE REVIEW
Major Depressive Disorder (MDD) presents a global challenge, with pharmacotherapy based on SSRIs and SNRIs remaining the standard of care. Despite clinical efficacy, the tolerability of these agents is often limited by iatrogenic Antidepressant-Associated Sexual Dysfunction (AASD), a leading cause of therapeutic non-adherence and so-called "hidden non-compliance," resulting in disease relapse. This paper provides a comprehensive literature review aimed at updating knowledge on epidemiology, neurobiological mechanisms extending beyond the serotonin hypothesis, and modern management strategies for AASD, with particular emphasis on Post-SSRI Sexual Dysfunction (PSSD). Databases including PubMed, ScienceDirect, Cochrane Library, and Google Scholar were searched, focusing on studies utilizing validated psychometric tools (e.g., ASEX, PRSexDQ). The analysis reveals a significant disparity between spontaneously reported AASD rates (10–15%) and those detected via screening (70–80%). A risk hierarchy was confirmed: paroxetine and venlafaxine demonstrate the highest iatrogenic potential, attributed partly to nitric oxide synthase inhibition and dopaminergic suppression. Vortioxetine and bupropion are characterized by a neutral profile, offering a safe alternative. The review also confirms the growing clinical importance of PSSD as a persistent complication. AASD requires proactive monitoring in daily practice. Results support moving away from a "wait and see" strategy in favor of routine screening and early implementation of switching or augmentation strategies. Personalization of pharmacotherapy is crucial for maintaining patient adherence and ensuring long-term depression treatment efficacy.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
THE IMPACT OF POLYCYSTIC OVARY SYNDROME ON MENTAL HEALTH AND BODY IMAGE IN WOMEN: A CLINICAL LITERATURE REVIEW
Polycystic ovary syndrome (PCOS) represents the most common endocrine disorder in women of reproductive age, affecting 6–20% of this population depending on diagnostic criteria applied. Beyond its metabolic and reproductive consequences, PCOS significantly impacts mental health, particularly depression, anxiety, and body image disturbance. This clinical literature review synthesizes evidence from clinical studies and observational research examining the psychological burden of PCOS. Evidence indicates that women with PCOS experience markedly elevated rates of depression (approximately 49%) and anxiety compared to healthy controls, with depression predominantly presenting as mild to moderate severity. Lifestyle factors, including lack of exercise (OR=7.5), psychological stress (OR=6.5), sleep disturbance, and high-fat diet, constitute significant modifiable risk factors for depression. Body image disturbance emerges as a critical mediating factor between PCOS symptoms and psychological distress, affecting quality of life and overall well-being. Body appreciation, in contrast to mere absence of dissatisfaction, constitutes a particularly important protective factor for mental health. Cognitive-behavioral therapy (CBT) and psychosocial interventions demonstrate substantial efficacy in reducing depression and anxiety symptoms. Routine mental health screening and implementation of evidence-based psychological interventions are essential components of comprehensive PCOS care. This review emphasizes the necessity of integrated, multidisciplinary approaches addressing both physical and psychological aspects of PCOS, with particular attention to lifestyle modification as a therapeutic strategy.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessTHE IMPACT OF POLYCYSTIC OVARY SYNDROME ON MENTAL HEALTH AND BODY IMAGE IN WOMEN: A CLINICAL LITERATURE REVIEW
Polycystic ovary syndrome (PCOS) represents the most common endocrine disorder in women of reproductive age, affecting 6–20% of this population depending on diagnostic criteria applied. Beyond its metabolic and reproductive consequences, PCOS significantly impacts mental health, particularly depression, anxiety, and body image disturbance. This clinical literature review synthesizes evidence from clinical studies and observational research examining the psychological burden of PCOS. Evidence indicates that women with PCOS experience markedly elevated rates of depression (approximately 49%) and anxiety compared to healthy controls, with depression predominantly presenting as mild to moderate severity. Lifestyle factors, including lack of exercise (OR=7.5), psychological stress (OR=6.5), sleep disturbance, and high-fat diet, constitute significant modifiable risk factors for depression. Body image disturbance emerges as a critical mediating factor between PCOS symptoms and psychological distress, affecting quality of life and overall well-being. Body appreciation, in contrast to mere absence of dissatisfaction, constitutes a particularly important protective factor for mental health. Cognitive-behavioral therapy (CBT) and psychosocial interventions demonstrate substantial efficacy in reducing depression and anxiety symptoms. Routine mental health screening and implementation of evidence-based psychological interventions are essential components of comprehensive PCOS care. This review emphasizes the necessity of integrated, multidisciplinary approaches addressing both physical and psychological aspects of PCOS, with particular attention to lifestyle modification as a therapeutic strategy.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
TIRZEPATIDE AND RETATRUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: CURRENT EVIDENCE AND FUTURE DIRECTIONS. A SYSTEMATIC REVIEW OF CURRENT LITERATURE
Background: The global prevalence of obesity and type 2 diabetes mellitus (T2DM) has achieved unprecedented levels, imposing substantial burdens on healthcare systems worldwide. Incretin-based pharmacotherapies have fundamentally transformed therapeutic approaches to these metabolic disorders over the past decade. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide additionally targets glucagon receptors. Both agents represent groundbreaking advances in metabolic pharmacotherapy. Objective: This comprehensive review synthesizes clinical evidence from trials conducted between 2014 and 2024, examining pharmacological mechanisms, therapeutic efficacy, safety characteristics, and prospective clinical applications of these novel multi-receptor agonists. Methods: We performed systematic literature searches across PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases. Selection criteria encompassed randomized controlled trials, systematic reviews, meta-analyses, and prospective cohort studies, adhering to PRISMA methodology throughout. Results: Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points. Phase 2 trials of retatrutide revealed even more remarkable outcomes, with weight reductions approaching 24.2% over 48 weeks. Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern. Conclusions: These pharmacological agents represent paradigm-shifting developments in obesity and diabetes management. Their therapeutic effectiveness approximates outcomes previously achievable only through surgical intervention, marking a transformative milestone for pharmacotherapy. Ongoing phase 3 trials will further elucidate their optimal positioning within clinical treatment algorithms.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTIRZEPATIDE AND RETATRUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: CURRENT EVIDENCE AND FUTURE DIRECTIONS. A SYSTEMATIC REVIEW OF CURRENT LITERATURE
Background: The global prevalence of obesity and type 2 diabetes mellitus (T2DM) has achieved unprecedented levels, imposing substantial burdens on healthcare systems worldwide. Incretin-based pharmacotherapies have fundamentally transformed therapeutic approaches to these metabolic disorders over the past decade. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide additionally targets glucagon receptors. Both agents represent groundbreaking advances in metabolic pharmacotherapy. Objective: This comprehensive review synthesizes clinical evidence from trials conducted between 2014 and 2024, examining pharmacological mechanisms, therapeutic efficacy, safety characteristics, and prospective clinical applications of these novel multi-receptor agonists. Methods: We performed systematic literature searches across PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov databases. Selection criteria encompassed randomized controlled trials, systematic reviews, meta-analyses, and prospective cohort studies, adhering to PRISMA methodology throughout. Results: Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points. Phase 2 trials of retatrutide revealed even more remarkable outcomes, with weight reductions approaching 24.2% over 48 weeks. Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern. Conclusions: These pharmacological agents represent paradigm-shifting developments in obesity and diabetes management. Their therapeutic effectiveness approximates outcomes previously achievable only through surgical intervention, marking a transformative milestone for pharmacotherapy. Ongoing phase 3 trials will further elucidate their optimal positioning within clinical treatment algorithms.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
EFFECTS OF BLUE LIGHT EXPOSURE ON RAPID EYE MOVEMENT SLEEP DURATION AND MELATONIN LEVELS IN CHILDREN: A COMPREHENSIVE LITERATURE REVIEW
Blue light exposure from electronic devices has emerged as a significant environmental factor affecting children's sleep architecture and circadian physiology. This comprehensive literature review synthesizes empirical evidence from 2020-2025 examining the effects of blue light exposure on rapid eye movement (REM) sleep duration and melatonin levels in pediatric populations. A systematic search of PubMed, Web of Science, and related databases identified studies employing objective measurement methods, including polysomnography (PSG) and actigraphy validated against PSG, with melatonin measurement via salivary DLMO. The current evidence demonstrates that blue light exposure, particularly from electronic devices in the evening hours, significantly suppresses melatonin production in children even at very low illuminance levels (5-40 lux), producing melatonin suppression of 70-99% depending on light intensity and spectral composition. Blue light predominantly affects melatonin suppression and REM sleep through intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing melanopsin with peak sensitivity at approximately 480 nm. Studies indicate that evening blue light exposure reduces REM sleep duration, increases REM fragmentation with elevated microarousals, increases sleep onset latency, and impairs sleep efficiency in children. The magnitude of effects on REM sleep and melatonin suppression demonstrates circadian timing dependency, with exposure during 21:00-22:30 hours producing maximum sleep disruption. Evening screen use, particularly interactive forms, is associated with delayed sleep onset and reduced total sleep duration in children measured via objective actigraphy. Interventions restricting blue light exposure before bedtime through screen abstinence and blue light-blocking glasses show slight improvements in sleep timing and circadian phase advancement. This review concludes that evidence-based guidelines recommending screen restriction in the 1-2 hours before bedtime are justified based on documented physiological mechanisms and objective sleep disruption in children.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessEFFECTS OF BLUE LIGHT EXPOSURE ON RAPID EYE MOVEMENT SLEEP DURATION AND MELATONIN LEVELS IN CHILDREN: A COMPREHENSIVE LITERATURE REVIEW
Blue light exposure from electronic devices has emerged as a significant environmental factor affecting children's sleep architecture and circadian physiology. This comprehensive literature review synthesizes empirical evidence from 2020-2025 examining the effects of blue light exposure on rapid eye movement (REM) sleep duration and melatonin levels in pediatric populations. A systematic search of PubMed, Web of Science, and related databases identified studies employing objective measurement methods, including polysomnography (PSG) and actigraphy validated against PSG, with melatonin measurement via salivary DLMO. The current evidence demonstrates that blue light exposure, particularly from electronic devices in the evening hours, significantly suppresses melatonin production in children even at very low illuminance levels (5-40 lux), producing melatonin suppression of 70-99% depending on light intensity and spectral composition. Blue light predominantly affects melatonin suppression and REM sleep through intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing melanopsin with peak sensitivity at approximately 480 nm. Studies indicate that evening blue light exposure reduces REM sleep duration, increases REM fragmentation with elevated microarousals, increases sleep onset latency, and impairs sleep efficiency in children. The magnitude of effects on REM sleep and melatonin suppression demonstrates circadian timing dependency, with exposure during 21:00-22:30 hours producing maximum sleep disruption. Evening screen use, particularly interactive forms, is associated with delayed sleep onset and reduced total sleep duration in children measured via objective actigraphy. Interventions restricting blue light exposure before bedtime through screen abstinence and blue light-blocking glasses show slight improvements in sleep timing and circadian phase advancement. This review concludes that evidence-based guidelines recommending screen restriction in the 1-2 hours before bedtime are justified based on documented physiological mechanisms and objective sleep disruption in children.